The efficacy of BAY y 1015 in dextran sulfate model of mouse colitis

Inflammation Research

Volumn 46, Issue 6, 1997, Pages 224-233

  Murthy, S ^a   Murthy, N S ^a   Coppola, D ^b   Wood, D L ^c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c BAYER CORPORATION   (United States)

Author keywords

5 Lipoxygenase inhibition; Dextran sulfate; Experimental colitis; Five lipoxygenase activating protein (FLAP); Inflammatory bowel disease; Leukotriene B4

Indexed keywords

ARACHIDONIC ACID; BAY Y 1015; DEXTRAN SULFATE; LEUKOTRIENE; LEUKOTRIENE B4; LIPOXYGENASE INHIBITOR; MYELOPEROXIDASE; OLSALAZINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM HEMORRHAGE; DRUG EFFICACY; ENTERITIS; FECES ANALYSIS; FEMALE; HISTOLOGY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; WEIGHT REDUCTION;

ANIMALS; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; LEUKOTRIENE B4; LIPOXYGENASE INHIBITORS; MICE; PEROXIDASE; QUINOLINES;

EID: 0030824886     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050177     Document Type: Article

References (38)

1. Jewell DP. Corticosteroids for the management of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1989;18:21-34.
2. Das K. Sulfasalazine therapy in inflammatory bowel disease. Gastroenterol Clin North Am 1989;18:1-20.
3. Shanahan F, O'Sullivan GC, Collins K. Immunosuppressive agents in inflammatory bowel disease: Current status and future prospects. Can J Pharmacol 1994;8:383-7.
4. 4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1994;86:453-60.
5. 14C)-arachidonic acid by human colonic mucosa. Gut 1983;24:1176-82.
6. Peskar BM, Dreyling KW, Peskar BA, May B, Goebell H. Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicyclic acid. Agents Actions 1986;18:381-3.
7. 4, a potent chemoldnetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980;286:264-5.
8. Bokoch GM, Reed PW. Effect of various lipoxygenase metabolites of arachidonic acid on degranulation of polymorphonuclear leukocytes. J Biol Chem 1981;256:5317-20.
9. Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994;344:859-61.
10. Rask-Madsen J, Bukhave K, Laursen LS, Lauritsen K. 5-lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents Actions 1992 (Special Conference Issue): C37-46.
11. Wallace JL, Macnaughton WK, Morris GP, Beck PL. Inhibition of leukotriene synthesis markedly accelerates healing in rat model of inflammatory bowel disease. Gastroenterology 1989;96:29-36.
12. Laursen LS, Naesdal J, Bukhave K, et al. Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet 1989;335:683-5.
13. 4 receptor antagonist, SC-41930, on acetic acid-induced colonic inflammation. Agents Actions 1989;27:395-7.
14. Miller DK, Gillard JW, Vickers P, Sadowski S, Leville C, Mancini JA, et al. Identification and isolation of a membrane protein necessary for leukotriene synthesis. Nature 1990;343:278.
15. Mancini JA, Abramovitz M, Cox ME, Wong E, Charleson S, Perrier H, et al. 5-lipoxygenase-activating protein 5 an arachidonate binding protein. FEBS Lett 1993;318:277-81.
16. Charleson S, Evans JF, Lerger F, Perrier H, Prasit P, Wang Z, et al. Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating protein. Eur J Pharmacol 1994;267: 275-80.
17. Mancini JA, Prasit P, Coppolino MG, Charleson P, Legers S, Evans JF, et al. 5-lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors. Mol Pharmacol 1992;41: 267-72.
18. Diamant Z, Timmer MC, van der Veen H, Page CP, van der Meer EJ, Stark PJ. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced air way responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995; 95:42-51.
19. Wallace JM, Keenan CM. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol 1990;258:G527-34.
20. 4) and systemic leukotriene production by a cycle, one dose q MK-591 in patients with active ulcerative colitis. A double blind placebo controlled study. Gastroenterology 1994;106:A698.
21. Hillingso J, Kjeldsen J, Laursen LS, Lauritsen K, von Spreckelsen S, Depre M, et al. Blockade of leukotriene production by a single oral dose of MK-0591 in active ulcerative colitis. Clin Pharmacol Ther 1995;57:335-41.
22. Cooper HS, Murthy SNS, Shah RS, Sedergran D. Clinicopathological study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69:238-49.
23. Murthy SNS, Cooper HS, Shim H, Shar RS, Ibrahim S, Sedergran D. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporine. Dig Dis Sci 1993;38:1722-34.
24. Murthy S, Cooper HS, Coppola D, Shirer R. Interleukin-1 receptor antagonist is effective against dextran sulfate (DSS)-mediated colitis in mice. Gastroenterology 1992;102:A669.
25. Murthy S, Cooper HS, McKibbin R, Coppola D, Shirer R. Transforming growth factor beta2, but not epidermal growth factor yields protection against dextran sulfate (DSS)-mediated colitis in mice. Gastroenterology 1992; 102:A669.
26. Murthy SNS, Fondacaro JD, Murthy NS, Cooper HS, Bolkenius F. Beneficial effect of MDL 73404 in dextran sulfate-mediated murine colitis. Agents Actions 1994;41 (Special Conference Issue):C233-4.
27. Matzke M, Beckerman B, Fruchtman R, Fugman B, Gardiner PJ, Goossens J, et al. Leukotriene synthesis inhibitors of the ourinoline type: parameters for the optimization of efficacy. Eur J Med Chem 1995;30(suppl):441S-451S.
28. Fruchtman R, Mohrs K-H, Hatzelman A, Raddatz S, Fugman B, Junge B, et al. In vitro pharmacology of Bay x 1005, a new inhibitor of leukotriene synthesis. Agents Actions 1993;38:188-95.
29. Kast R, Fruchtman R, Kupferschmidt R, Mohrs KH, Raddatz S. Muller-Peddinghaus R, et al. Role of 5-lipoxygenase-activating protein in the regulation of 5-lipoxygenase activity in human neutrophils. Agents Actions 1994;41(Special Conference Issue):C166-8.
30. Gorene I, Habat C, Gascard JP, Norel X, Muller-Peddinghaus R, Mohrs KH, et al. (R)-2-[4-Quinolin-yl-methoxy) phenyl]-2-cryclopentyl] acetic acid (BAY x 1005), a potent leukotriene synthesis inhibitor: Effects on anti-IgE challenge in human airways. J Pharmacol Exp Ther 1994;268: 868-72.
31. Hatzelman A, Fruchtman R, Mohrs KH, Raddatz S, Matzke M, Pleiss V, et al. Mode of action of the new selective leukotriene synthesis inhibitor BAY x 1005. {(R)-2-{4-(quinolin-2yl-methoxy)phenyl]-2 cyclopentylacetic acid} and structurally related compounds. Biochem Pharmacol 1993;45:101-11.
32. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation. Estimation of neutrophil content with enzyme marker. J Invest Dermatol 1982;78:206-9.
33. Peskar BM. Role of sulfidopeptide leukotrienes in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1989;1:160-5.
34. 4 potentiates colonic ulceration in the rat. Dig Dis Sci 1990;91:837-4.
35. Wallace JL, Whittle BJR, Boughton-Smith NK. Prostaglandin protection of rat colonic mucosa from damage induced by ethanol. Dig Dis Sci 1985;30:866-76.
36. Hawkey C, Gassull M, Lauritsen K, Martin F, O'Morain C, Rask-Madsen J, et al. Efficacy of Zileuton, a 5-lipoxygenase inhibition, in the maintenance of remission in patients with ulcerative colitis. Gastroenterology 1994;106:A695.
37. Peppercorn M, Das K, Elson C, Geraci, K, Robinson M, Rubin A, et al. Zileuton, a 5-lipoxygenase inhibitor, in treatment of active ulcerative colitis. Gastroenterology 1994;106:A751.
38. 4 receptor antagonist SC 41930 in colitic cotton-top tamarins. Agents Actions 1994;41(Special Conference Issue):C254-5.